Sartorius Stedim Biotech reported a robust EBITDA margin of 30.8% for 2025, a 2.8 percentage point increase, driven by strong performance in its consumables business. The French-based unit of the German company also saw a 9.6% constant-currency revenue growth, reaching €2.97 billion. This financial success reflects the company's strategic focus and market positioning.

The company's Bioprocess Solutions Division saw a 9.5% constant-currency growth, contributing significantly to the positive results. Despite a slight miss on fourth-quarter sales estimates, the overall performance was strong. The company's focus on consumables, which have higher margins, is key to its profitability and growth in the biotech space.

For 2026, Sartorius Stedim Biotech anticipates sales revenue growth of 6% to 10%, with an EBITDA margin slightly above 31%. The guidance reflects normalization in market dynamics. The company is also investing in expansion, strengthening its position in the competitive biotech sector.

Sartorius's success highlights the growing demand for bioprocessing products. As the company continues to expand and invest in production, it is well-positioned to capitalize on the increasing trends in the biopharmaceutical industry. The company's focus on high-margin consumables is likely to continue driving profitability.